<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169604/" ref="ordinalpos=2936&amp;ncbi_uid=3224360&amp;link_uid=PMC3169604" image-link="/pmc/articles/PMC3169604/figure/pone-0024468-g006/" class="imagepopup">Figure 6. Effect of vorinostat on the mTor and Ampk <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in endometrial cancer cells..  From: The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>. </a></div><br /><div class="p4l_captionBody">Ishikawa and USPC-2 cells were treated with vorinostat and/or IGF-I, and cell lysates (100 Âµg) were prepared after 24 h. Western blot analysis was performed with antibodies against pmTor, T-mTor, p-Ampk, T-Ampk, p21, cyclin D1, PI3K and actin. The figure shows the results of a typical experiment, repeated three times with similar results.</div></div>